PRESS RELEASE

July 2020

La FRENCH TECH

XYLYX BIO AND CELL&SOFT ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP NEXT-GENERATION CELL CULTURE PLATFORMS TO ACCELERATE CANCER DRUG DISCOVERY

CELL&SOFT, IN PARTNERSHIPS WITH RESEARCHERS FROM IBPS, PROVIDE A NEW STANDARD FOR HIPSCS EXPANSION AND MAINTENANCE

New York, USA - Grenoble, France, July 28th 2020 | New York-based Xylyx Bio, Inc. a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.

Existing in vitro models lack physiological relevance, yielding misleading and non-translatable results that slow essential progress needed to develop effective drugs capable of preventing thousands of cancer deaths each year.

The collaboration will initially focus on the development of products for lung adenocarcinoma. The combination of Xylyx Bio lung-specific ECM surface coatings and Cell&Soft soft cell culture plates will enable scientists to develop more physiologically relevant pre-clinical tumor models to substantially improve the identification and selection of effective lung cancer therapies.

Camille Migdal, Ph.D., President and Co-Founder of Cell&Soft, said, "We are excited about combining our soft cell culture plates mimicking lung rigidity with Xylyx Bio lung-specific extracellular matrix to bring much-needed highly specific microenvironments to lung cancer studies". Andrea Nye, President & CEO of Xylyx Bio, explained, "Collaborative relationships with innovative companies like Cell&Soft support the creation of improved tools that enable researchers to better model disease biology and increase predictability of drug efficacy, and help shift the overall paradigm from entrenched, non-predictive in vitro models to more accurate and actionable drug discovery."

Cell&Soft

ABOUT XYLYX BIO

As a global leader in specialized ECM-based biomaterials and corresponding clinical data and contract R&D services that enable insight into disease biology and the efficacy of drug candidates, Xylyx Bio is implementing a new vision for how advanced biological systems can contribute to improved health and quality of life for patients in need.

ABOUT CELL&SOFT

Cell&Soft is a French biotech company based in Grenoble, France. It is a spinoff from the Microelectronics Technologies Laboratory (CNRS) and the Grenoble Biosciences and Biotechnologies Institute (CEA BIG/IRIG), and was incubated within the Linksium SATT, Grenoble. Cell&Soft is specialized in the development of soft or rigidity-textured cell culture plates made up of synthetic hydrogels reproducing the flexibility of human and animal tissues.

For the first time, physiological stiffness supports combine unprecedented control of mechanical properties at the micrometric scale with independent control of surface chemistry. Cell&Soft offers an in vitro culture environment with robust chemo-mechanical characteristics that support long cultures without degradation or modification of their physical properties. Standard biochemical and cellular analysis procedures remain unchanged. The supports are available in 10 stiffnesses, 5 surface chemistries and 6 formats (from BP35 to p96).

Contact
Rachel MARTIN
Portable : +33 6 33 39 31 69
rachel.martin@cellandsoft.com
-
Tanya Yankelevich
Director of Product Management
Xylyx Bio, Inc.
tanya@xylyxbio.com